

EXHIBIT A

Edward T. Wei
Professor of Toxicology
School of Public Health
University of California
Berkeley, California 94720

Res: 480 Grizzly Peak, Berkeley, CA 94708

Office: 510-642-0804
Lab: 510-642-9632

email: etwei@uclink.berkeley.edu
Fax: 510-642-5815

Degrees:

A.B., Physiology, University of California, Berkeley, 1965.

Ph.D., Pharmacology and Comparative Toxicology, University of California, San Francisco Medical Center, 1969.

Academic Experience:

Professor of Toxicology (1981-present), *Associate Professor* (1975-1981), and *Assistant Professor* (1970-1975), School of Public Health, University of California, Berkeley.

Associate Professor and Assistant Professor, Department of Pharmacology and Toxicology, School of Medicine, University of California, San Francisco (1972-1981).

Senior Fogarty International Fellowship, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom (1984-1985), Sponsors: Sir James Black and Terry W. Smith.

Visiting Scientist, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom (1983).

Visiting Scientist, Professor W. Feldberg's Laboratory, National Institute of Medical Research, London, United Kingdom (1977,1978).

Post-doctoral Fellow, Stanford University (1969-1970) (Adviser: F.E. Yates).

Professional Experience:

- Member of the Committee on the Assessment of Human Health Effects of Great Lakes Water Quality, International Joint Commission (1984-1990).
- Provided consultation for Broward County and Fremont City on "Public Health Aspects of Non-Criteria Pollutants to Be Emitted from Proposed Recovery Facilities" (1985-1991).
- Expert consultant to review Health Assessment Documents for the City of San Diego Wastewater Recovery Project. San Pasqua Facility, Wastewater Treatment Plant (1995-1997).

- External scientific reviewer of “Draft of Public Health Goal (PHG) for methyl-tert-butyl ether in drinking water.” Pesticide and Environmental Toxicology Section. Office of Environmental Health Assessment, California Environmental Protection Agency. This draft document can be found on the Internet (1998).
- External peer reviewer of proposed Bay Protection Toxic Cleanup Program’s Regional Toxic Hot Spot Cleanup Plans. California State Water Resources Control Board, California Environmental Protection Agency (1998).
- Scientific Consultant for Neurobiological Technologies, Inc. (1990-1997) and for SciClone Pharmaceuticals (1997-1998).

Society Memberships:

Phi Beta Kappa, American Society for Pharmacology and Experimental Therapeutics, Western Pharmacology Society, International Narcotics Research Conference.

Research Areas and Grants:

Research grants (including a Merit Award) from the National Institute on Drug Abuse for research on chemicals affecting the nervous system (1971-1998).

Training grant from the National Institute on Occupational Health and Safety (1970-1990).

Various small research grants were held on chemical carcinogens, heavy metals, asbestos and antihypertensive drugs.

Current research focused on the use of neuropeptides to inhibit inflammation produced by noxious physical and chemical agents and to inhibit angiogenesis and tumor growth.

Inventions

<u>Title of Patent</u> (ET Wei is the Principal Inventor)	<u>Date Issued</u>	<u>US Patent No.</u>
1. Melanocortin receptor antagonists and modulations of melanocortin receptor activity	filed March, 1998	pending
2. Treatment to reduce edema	05/20/1997	US5631226
3. Treatment to reduce edema	01/30/1996	US5488033
4. Anti-inflammatory composition and method with des-Tyr dynorphin and analogues	01/09/1996	US5482930
5. Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues	01/02/1996	US5480869

6. Neurotensin method for inhibiting vascular leakage	12/20/1994	US5374621
7. Method for treating endotoxin shock with CRF	04/26/1994	US5306710
8. Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues	01/05/1993	US5177060
9. Treatment to reduce edema for brain and musculature injuries	08/11/1992	US5137871
10. Method of inhibiting inflammatory response	01/31/1989	US4801612

Publications

1. E.T. Wei, L.C.K. Wong, and C.H. Hine. Selective potentiation of carbon tetrachloride hepatotoxicity by ethanol. *Archives Internationales Pharmacodynamie et de Therapie* 189: 5-11, 1971.
2. E.T. Wei, L.C.K. Wong, and C.H. Hine. Potentiation of carbon tetrachloride hepatotoxicity by ethanol and cold. *Toxicology and Applied Pharmacology* 18: 329-334, 1971.
3. L. Dales, E. Kahn, and E.T. Wei. An assessment of the methylmercury hazard in California. *California Medicine* 114: 13-15, 1971.
4. E.T. Wei and R.C. Spear. The fatal dose of methylmercury in man. *Journal of the American Medical Association (Letter to the Editor)* 216: 1347, 1971.
5. R.C. Spear and E.T. Wei. Dynamic aspects of environmental toxicology. *Journal of Dynamic Systems, Measurement and Control* 93: 114-118, 1972.
6. B. Garber and E.T. Wei. Adaptation to the toxic effects of lead. *American Industrial Hygiene Association Journal* 33: 756-760, 1972.
7. B. Garber and E.T. Wei. Lead toxicity in mice with genetically different levels of delta-aminolevulinic acid dehydratase. *Bulletin of Environmental Contamination and Toxicology* 9: 80-83, 1973.
8. J. Sinow and E.T. Wei. Ocular toxicity of paraquat. *Bulletin of Environmental Contamination and Toxicity* 9: 163-168, 1973.
9. P. Jacobsen, R.C. Spear, and E.T. Wei. Parathion and diisopropylfluorophosphate (DFP) toxicity in partially-hepatectomized rats. *Toxicology and Applied Pharmacology* 26: 314-317, 1973.
10. D. Null, P. Gartside, and E.T. Wei. Methylmercury accumulation in the brain of pregnant, non-pregnant, and fetal rats. *Life Sciences (Part 2)* 12: 65- 72, 1973.

11. R.C. Spear and E.T. Wei. Probabilistic assessment of methylmercury toxicity. In: *Mercury in the Western Environment*, Donald P. Buhler (ed.), Oregon State University Press, Corvallis, Oregon, pp. 320- 327, 1974.
12. B. Garber and E.T. Wei. Influence of dietary factors on the gastrointestinal absorption of lead. *Toxicology and Applied Pharmacology* 27: 685-691, 1974.
13. R. Talcott, M. Hollstein, and E.T. Wei. Mutagenicity of 8-hydroxyquinoline and related compounds in the *Salmonella typhimurium* bioassay. *Biochemical Pharmacology* 25: 1323-1328, 1976.
14. W.G. Light and E.T. Wei. Surface charge and hemolytic activity of asbestos. *Environmental Research* 13: 135-145, 1977.
15. W.G. Light and E.T. Wei. Surface charge and asbestos toxicity. *Nature (London)* 265: 537-539, 1977.
16. R. Talcott and E.T. Wei. Airborne mutagens bioassayed in *Salmonella typhimurium*. *Journal of the National Cancer Institute* 58: 449-451, 1977.
17. N. Kado and E.T. Wei. Radioimmunoassay for benzo(a)pyrene. *Journal of National Cancer Institute* 61: 221-225, 1978.
18. M. Hollstein, R. Talcott, and E.T. Wei. Quinoline, conversion to a mutagen by rodent and human liver. *Journal of the National Cancer Institute* 60: 405-410, 1978.
19. Y. Wang, S.M. Rappaport, R. Sawyer, R. Talcott, and E.T. Wei. Direct-acting mutagens in automobile exhaust. *Cancer Letters* 5: 39-47, 1978.
20. F.W. Busch, D.A. Seid, and E.T. Wei. Substitute-tobacco tar toxicity (Letter to Editor). *Lancet* ii: 614, 1978.
21. F.W. Busch, D.A. Seid, and E.T. Wei. Mutagenic activity of marihuana smoke condensates. *Cancer Letters* 6: 319-324, 1979.
22. S.M. Rappaport, M.C. McCartney, and E.T. Wei. Volatilization of mutagens from beef during cooking. *Cancer Letters* 8: 139-145, 1979.
23. R. Talcott, H. Shu, and E.T. Wei. Dissociation of microsomal oxygen reduction and lipid peroxidation with the electron acceptors, paraquat, diquat, and menadione. *Biochemical Pharmacology* 28: 665-671, 1979.
24. H. Shu, R. Talcott, S. Rice, and E.T. Wei. Lipid peroxidation and paraquat toxicity. *Biochemical Pharmacology* 28: 327-331, 1979.

25. W.G. Light and E.T. Wei. Surface charge and the molecular basis of asbestos toxicity. Proceedings of the International Conference on Asbestos, Wales, 1980. Academic Press, New York, pp. 139-145, 1980.
26. E.T. Wei, Y.Y. Wang, and S.M. Rappaport. Diesel emissions and the Ames test: A commentary. *Journal of the Air Pollution Control Association* 30: 267-271, 1980.
27. S.M. Rappaport, Y.Y. Wang, E.T. Wei, R. Sawyer, B.E. Watkins, H. Rapoport. Isolation and identification of a direct-acting mutagen in diesel-exhaust particles. *Environmental Science and Technology* 14: 1505-1508, 1980.
28. Y.Y. Wang, D. Seid, R. Talcott, and E.T. Wei. Antimutagenic properties of liver homogenates, proteins, and glutathione on diesel exhaust particles. *Cancer Letters* 11: 266-275, 1981.
29. J.P. Nachtman, X.B. Xu, S.M. Rappaport, R.E. Talcott, and E.T. Wei. Mutagenic activity in diesel exhaust particles. *Bulletin of Environmental Contamination and Toxicology* 27: 463-466, 1981.
30. X.B. Xu, J.P. Nachtman, S.M. Rappaport, and E.T. Wei. Identification of 2-nitrofluorene in diesel exhaust particles. *Journal of Applied Toxicology* 1: 196-198, 1981.
31. Z.L. Jin, X.B. Xu, J.P. Nachtman, and E.T. Wei. Potent mutagenic impurities in a commercial sample of 3-nitro-9-fluorenone. *Cancer Letters* 15: 209-214, 1982.
32. X.B. Xu, J.P. Nachtman, Z.L. Jin, E.T. Wei, and S.M. Rappaport. Isolation and identification of mutagenic nitro-polycyclic aromatic hydrocarbons in diesel-exhaust particles. *Analytica Chimica Acta* 136: 163-174, 1982.
33. J.P. Nachtman and E.T. Wei. Evidence for enzymatic reduction of 1-nitropyrene by rat liver fractions. *Experientia* 38: 837-838, 1982.
34. B. Mossman, W. Light, and E.T. Wei. Asbestos: Mechanisms of toxicity and carcinogenicity in the respiratory tract. *Annual Review of Pharmacology and Toxicology* 23: 595-615, 1983.
35. E.T. Wei and H.P. Shu. Nitroaromatic carcinogens in diesel engine exhausts: A review of recent laboratory findings. *American Journal of Public Health* 73: 1085-1088, 1983.
36. E.T. Wei. Resource recovery facilities, air pollution and public health safety. A review of the literature. Report completed for the Minnesota Air Pollution Control Agency, April 1, 1986.
37. X.B. Xu, E.T. Wei, and A.L. Burlingame. Identification of sulfur-containing polycyclic aromatic hydrocarbons in diesel exhaust particulates by high resolution mass spectrometry and capillary column gas chromatography/high resolution mass spectrometry. Beijing Conference and Exhibition on Instrumental Analysis, November 25, 1985 (Beijing).
38. M. Lotti, E.T. Wei, R.C. Spear, and C.E. Becker. Neurotoxic esterase in rooster testis. *Toxicology and Applied Pharmacology* 77: 175-180, 1985.

Pharmacology Research

39. E.T. Wei and J.T. Wilson. Stress mediated decrease in liver hexobarbital metabolism: The role of corticosterone and somatotropin. *Journal of Pharmacology and Experimental Therapeutics* 177: 227-233, 1971.
40. E.T. Wei, H.H. Loh, and E.L. Way. Neuroanatomical correlates of morphine dependence. *Science* 177: 616-617, 1972.
41. E.T. Wei and H.H. Loh. Morphine dependence unaltered by previous dependence on morphine. *Nature (London)* 238: 396-397, 1972.
42. E.T. Wei, J. Maran, A.P. Dhariwal, and F.E. Yates. Regional responses of the pituitary to corticotropin-releasing factor (CRF) and ammonium ions. *Endocrinology* 92: 710-715, 1973.
43. E.T. Wei, H.H. Loh, and E.L. Way. Quantitative aspects of precipitated abstinence in morphine-dependent rats. *Journal of Pharmacology and Experimental Therapeutics* 184: 398-403, 1973.
44. E.T. Wei. Assessment of precipitated abstinence in morphine-dependent rats. *Psychopharmacologia* 28: 35-44, 1973.
45. E.T. Wei. Morphine analgesia, tolerance and physical dependence in the adrenalectomized rat. *British Journal of Pharmacology* 47: 693-699, 1973.
46. E.T. Wei, H.H. Loh, and E.L. Way. Brain sites of precipitated abstinence in morphine-dependent rats. *Journal Pharmacology and Experimental Therapeutics* 185: 108-115, 1973.
47. E.T. Wei. Brain lesions attenuating wet shake behavior in morphine-abstinent rats. *Life Sciences (Part 1)* 12: 385-392, 1973.
48. E.T. Wei, H.H. Loh, and E.L. Way. Neuroanatomical correlates of wet shake behavior in the rat. *Life Sciences (Part 2)* 12: 489-496, 1973.
49. L. Tseng, E.T. Wei, and H.H. Loh. Brain areas associated with bulbocapnine catalepsy. *European Journal of Pharmacology* 22: 263-366, 1973.
50. P.I. Collins, E.T. Wei, and E.L. Way. Central sites of morphine analgesia. *Proceedings of the Western Pharmacology Society* 17: 164-167, 1974.
51. E.L. Way, H.H. Loh, I.K. Ho, E. Iwamoto, and E.T. Wei. Neuroanatomical and chemical correlates of naloxone-precipitated withdrawal. In: *Narcotic Antagonists*, M.C. Braude, L.S. Harris, E.L. May, J.P. Smith, and J.E. Villarreal (eds.), *Advances in Biochemical Psychopharmacology* 8: 455-469, Raven Press, New York, 1974.

52. E.T. Wei, L.F. Tseng, H.H. Loh, and E.L. Way. Similarity of morphine abstinence signs to thermoregulatory behavior. *Nature (London)* 247: 398-400, 1974.
53. E.T. Wei and E.L. Way. Assessment of tolerance and physical dependence. In: *Methods in Narcotic Research*, S. Ehrenpreis (ed.), Marcel Dekker, New York, pp. 224-259, 1975.
54. E.T. Wei, S. Sigel, and E.L. Way. Regional sensitivity of the rat brain to the inhibitory effects of morphine on wet shake behavior. *Journal of Pharmacology and Experimental Therapeutics* 193: 56-63, 1975.
55. E.T. Wei, S. Sigel, H. Loh, and E.L. Way. Central sites of naloxone-precipitated shaking in the anesthetized morphine-dependent rat. *Journal of Pharmacology and Experimental Therapeutics* 195: 480-487, 1975.
56. E.L. Way, H.H. Loh, L.F. Tseng, and E.T. Wei. Behavioral and neurohormonal relationships to thermoregulatory adaptive changes in morphine abstinence. Kroc Foundation Symposia No. 2 on Drug Effects on Neuroendocrine Mechanisms. In: *Narcotics and the Hypothalamus*, pp. 9-23., E. Zimmerman and R. George (eds.), Raven Press, 1975:
57. E.T. Wei, S. Sigel, H.H. Loh and E.L. Way. Thyrotrophin-releasing hormone and shaking behaviour in the rat. *Nature (London)* 25: 739-740, 1975.
58. E.T. Wei. Resemblance of morphine antinociception to the central depressant actions of norepinephrine. *Life Sciences* 17: 17-18, 1975.
59. L.F. Tseng, H.H. Loh, and E.T. Wei. Effects of clonidine on morphine withdrawal signs in the rat. *European Journal of Pharmacology* 30: 93-99, 1975.
60. E.T. Wei, H. Loh, and E.L. Way. Potency of the N-methyl analog of TRH in the induction of shaking movements in the rat. *European Journal of Pharmacology* 36: 227-229, 1976.
61. H. Loh, L.F. Tseng, E.T. Wei, and C.H. Li. Beta-endorphin is a potent analgesic agent. *Proceedings of the National Academy of Sciences* 73: 2895-2898, 1976.
62. E.T. Wei. Chemical stimulants of shaking behavior. *Journal of Pharmacy and Pharmacology* 28: 722-724, 1976.
63. E.T. Wei and H. Loh. Physical dependence on opiate-like peptides. *Science* 193: 1262-1263, 1976.
64. W. Feldberg and E.T. Wei. Central origin and mechanism of action of morphine on the cardiovascular system as revealed by naloxone. *Journal of Physiology (London)* 272: 99-100, 1977.
65. W. Feldberg and E.T. Wei. Central sites of action of morphine when producing cardiovascular effects. *Journal of Physiology (London)* 275: 57, 1977.

66. E.T. Wei, H.H. Loh, L.F. Tseng, and C.H. Li. Comparison of the behavioral effects of beta-endorphin and enkephalin analogs. *Life Sciences* 21: 321-328, 1977.
67. P.Y. Law, E.T. Wei, L.F. Tseng, H.H. Loh, and E.L. Way. Opioid properties of beta-lipotropin fragment 60-65, H-Arg-Tyr-Gly-Gly-Phe- Met-OH. *Life Sciences* 20: 251-260, 1977.
68. W. Feldberg and E.T. Wei. Central cardiovascular effects of enkephalins and C-fragment of lipotropin. *Journal of Physiology (London)* 280: 18, 1978.
69. J.W. Holaday, E.T. Wei, H.H. Loh, and C.H. Li. β -Endorphin may function in heat adaptation. *Proc. Natl. Acad. Sci. USA* 75: 2923-2927, 1978.
70. E.T. Wei. Interaction of morphine with drugs which produce withdrawal-like syndromes. In: *Factors Affecting the Actions of Narcotics*. M. Adler, L. Manara, and R. Samanin (eds.). Monographs of the Mario Negri Institute for Pharmacological Research, Milano, Italy, pp. 147-157, Raven Press, New York, 1978.
71. H.H. Loh, L.F. Tseng, J.W. Holaday, and E.T. Wei. Endogenous peptides and opiate actions. In: *Factors Affecting the Actions of Narcotics*. M. Adler, L. Manara and R. Samanin (eds.). Monographs of the Mario Negri Institute for Pharmacological Research, Milano, Italy, pp. 387-402, Raven Press, New York, 1978.
72. W. Feldberg and E.T. Wei. Cardiovascular effects of hypertonic sodium chloride solutions when injected into the liquor space of anaesthetized cats. *British Journal of Pharmacology* 66: 51-54, 1979.
73. E.T. Wei and Y. Wu. Pressor effects of intracisternal Na^+ in normotensive and spontaneously hypertensive rats. *Brain Research* 169: 605-609, 1979.
74. L.F. Tseng, E.T. Wei, H.H. Loh, and C.H. Li. β -Endorphin: Central sites of analgesia, catalepsy, and body temperature changes in rats. *Journal of Pharmacology and Experimental Therapeutics* 214: 328-332, 1980.
75. E.T. Wei, A. Lee, and J.K. Chang. Cardiovascular effects of peptides related to the enkephalins and β -casomorphin. *Life Sciences* 26: 1517- 1522, 1980.
76. J.S. Morley and E.T. Wei. Hexahydro derivative of (D-Met²,Pro⁵) enkephalinamide gives rise to physical dependence. *International Journal of Peptide and Protein Research* 16: 254-258, 1980.
77. E.T. Wei. Enkephalin analogs and physical dependence. *Journal of Pharmacology and Experimental Therapeutics* 216: 12-18, 1981.
78. E.T. Wei. Pharmacological aspects of shaking behavior produced by AG-3-5, TRH, and morphine withdrawal. *Federation Proceedings* 40: 1491-1496, 1981.

79. W. Feldberg and E.T. Wei. Cardiovascular effects of morphine and of opioid peptides in anaesthetized cats. In: Central Nervous System Mechanisms in Hypertension, J.P. Buckley and C.M. Ferrario (eds.), New York, Raven Press, pp. 229-233, 1981.
80. G. Mues, I. Fuchs, E.T. Wei, E. Weber, C.J. Evans, J.D. Barchas, and J.K. Chang. Blood pressure elevation in rats by peripheral administration of Tyr-Gly-Gly-Phe-Met-Arg-Phe and the invertebrate neuropeptide Phe-Met-Arg-Phe-NH₂. *Life Sciences* 31: 2555-2561, 1982.
81. Y.Y. Wu and E.T. Wei. Infusions of chemicals into the brain and the development of sustained elevations of blood pressure in the rat. *Life Sciences* 30: 1537-1546, 1982.
82. F.J. Mycroft, E.T. Wei, J.E. Bernardin, and D.D. Kasarda. MIF-like sequences in milk and wheat protein. *New England Journal of Medicine* (correspondence) 307: 895, 1982.
83. K.J. Chang, P. Cuatrecasas, E.T. Wei, and J.K. Chang. Analgesic activity of intracerebroventricular administration of morphiceptin and beta-casomorphins: Correlation with the morphine receptor binding affinity. *Life Sciences* 30: 1547-1552, 1982.
84. C.R. Strong, P.P. Auerbach, J.K. Chang, and E.T. Wei. Unusual behavioral properties of some new opioid peptides. *Advances in Endogenous Opioids*, H. Takagi and E.J. Simon (eds.), pp. 347-349. Elsevier Biomedical Press, Amsterdam, the Netherlands, 1982.
85. E.T. Wei and D.A. Seid. AG-3-5: A chemical producing sensations of cold. *Journal of Pharmacy and Pharmacology* 35: 110-112, 1983.
86. E.T. Wei. Inhibition of shaking movements in rats by central administration of cholinergic and adrenergic agents. *Psychopharmacology* 81: 111-114, 1983.
87. J.G. Kiang and E.T. Wei. Inhibition of an opioid-evoked vagal reflex in rats by naloxone, SMS-201,995, and ICI 154,129. *Regulatory Peptides* 6: 255-262, 1983.
88. J.G. Kiang, W.L. Dewey, and E.T. Wei. Tolerance to morphine bradycardia in the rat. *Journal of Pharmacology and Experimental Therapeutics* 226: 187-191, 1983.
89. M. Dashwood, J.G. Kiang, and E.T. Wei. An etorphine-evoked vagal reflex in rats is inhibited by naloxone, N-methylnaloxone and SMS 201,995. *Archives Internationales de Pharmacodynamie et de Therapie* 266: 77-82, 1983.
90. K.J. Chang, E.T. Wei, A. Killian, and J.K. Chang. Morphiceptin analogs: Structure-activity studies and pharmacology. *Journal of Pharmacology and Experimental Therapeutics* 227: 403-408, 1983.
91. Y.Y. Wu and E.T. Wei. Mechanisms underlying the pressor responses to acute and chronic intraventricular administration of carbachol in the rat. *Journal of Pharmacology and Experimental Therapeutics* 228: 354-363, 1984.

92. J.G. Kiang and E.T. Wei. Sensitivity to morphine-evoked bradycardia in rats is modified by dynorphin (1-13), Leu enkephalin, and Met enkephalin. *Journal of Pharmacology and Experimental Therapeutics* 229: 469-474, 1984.
93. F. Mycroft and E.T. Wei. Pro-Leu-Gly-NH₂ and para-peptide inhibit development of tolerance to haloperidol catalepsy in the mouse. *Peptides* 5(5): 883-887, 1984.
94. J.G. Kiang and E.T. Wei. Peripheral opioid receptors influencing heart rate in rats: Evidence for endogenous tolerance. *Regulatory Peptides* 8: 297-303, 1984.
95. J. Tang, R. Webber, D. Chang, J.K. Chang, J.G. Kiang, and E.T. Wei. Depressor and natriuretic activities of several atrial peptides. *Regulatory Peptides* 9: 53-59, 1984.
96. E.T. Wei and J.G. Kiang. Peripheral opioid receptors influencing heart rate in rats. In: "Opioid Peptides in the Periphery", E. Fraioli, A. Isidori, M. Mazzetti (eds.). Elsevier Science Publishing, pp. 95-101, 1984.
97. E.T. Wei, N.M. Lee, and J.K. Chang. Method for controlling blood pressure. U.S. Patent No. 4,481,191. November 4, 1984.
98. T. Priestly, M.J. Turnbull, and E.T. Wei. In vivo evidence for the selectivity of ICI 154129 for the delta opiate receptor. *Neuropharmacology* 24: 107-110, 1985.
99. J.G. Kiang and E.T. Wei. CRF-Evoked bradycardia in urethane-anesthetized rats is blocked by naloxone. *Peptides* 6: 409-413, 1985.
100. W. Feldberg and E.T. Wei. Analysis of the cardiovascular effects of morphine in the cat. *Neurosciences* 17: 495-506, 1986.
101. S.Y.H. Tse and E.T. Wei. Inhibition of the shake response in rats by adenosine and 2-chloroadenosine. *Psychopharmacology* 90: 322-326, 1986.
102. E.T. Wei, J.G. Kiang, P. Buchan, and T.W. Smith. Corticotropin-releasing factor inhibits neurogenic plasma extravasation in the rat paw. *Journal of Pharmacology and Experimental Therapeutics* 238: 783-787, 1986.
103. E.T. Wei and J.G. Kiang. Inhibition of protein exudation from the trachea by corticotropin-releasing factor. *European Journal of Pharmacology* 140: 63-67, 1987.
104. E.T. Wei, J.G. Kiang, and J.Q. Tian. Anti-inflammatory activity of corticotropin-releasing factor. I. Efficacy studies. *Proceedings of the Western Pharmacology Society* 30: 59-62, 1987.
105. J.G. Kiang, L. Poree, and E.T. Wei. Anti-inflammatory activity of corticotropin-releasing factor. II. Mechanisms of action. *Proceedings of the Western Pharmacology Society* 30: 63-65, 1987.

106. M.R. Dashwood, H.E. Andrews, and E.T. Wei. Binding of (I^{125})-Tyr- corticotropin-releasing factor to rabbit aorta is reduced by removal of the endothelium. *European Journal of Pharmacology* 135: 111-112, 1987.
107. J.G. Kiang and E.T. Wei. Corticotropin-releasing factor inhibits thermal injury. *Journal of Pharmacology and Experimental Therapeutics* 243: 517-520, 1987.
108. F.J. Mycroft, H.N. Bhargava and E.T. Wei. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide. *Peptides* 8: 1051-1055, 1987.
109. E.T. Wei, J.G. Kiang and J.Q. Tian. Anti-Inflammatory actions of substance P antagonists and corticotropin-releasing factor on thermal injury to rat pawskin. *Regulatory Peptides* 22: 185, 1988.
110. E.T. Wei, S. Serda and J.Q. Tian. Protective actions of corticotropin-releasing factor on thermal injury to rat pawskin. *Journal of Pharmacology and Experimental Therapeutics* 247: 1082-1085, 1988.
111. J.Q. Tian and E.T. Wei. Acute inflammatory response of the rat pawskin to acid injury is attenuated by corticotropin-releasing factor. *Drug and Chemical Toxicology* 12: 61-66, 1989.
112. E.T. Wei and J.G. Kiang. Method of Inhibiting Inflammatory Response. United States Patent Number 4,801,612, Jan. 31, 1989. (Assignee: Regents of the University of California, Berkeley)
113. E.T. Wei and J.G. Kiang. Peptides of the corticoliberin superfamily inhibit thermal and neurogenic inflammation. *European Journal of Pharmacology* 168: 81-86, 1989.
114. L. Poree, A.H. Dickenson and E.T. Wei. Corticotropin-releasing factor inhibits the response of trigeminal neurons to noxious heat. *Brain Research* 502: 349-355, 1989.
115. E.T. Wei, J.C. Wong and J.G. Kiang. Decreased inflammatory responsiveness of hypophysectomized rats to heat is reversed by a corticotropin-releasing factor (CRF) antagonist. *Regulatory Peptides* 27: 317-323, 1990.
116. W.L. Joyner, and E.T. Wei. Mechanism for the anti-inflammatory effect of corticotropin-releasing factor (CRF). *FASEB Journal* 3: 272, 1989. (Abstract)
117. W.L. Joyner, B.A. Macek, and E.T. Wei. Inhibition of the bradykinin induced inflammation by corticotropin-releasing factor (CRF). *FASEB Journal* 4: 1123, 1990. (Abstract)
118. E.T. Wei, G.C. Gao and D.I. Sessler. CRF inhibits the flare response to intradermal histamine in man. *Clinical Pharmacology and Therapeutics* 47: 192 (1990). (Abstract)
119. O. Babuna, G.C. Gao, E.T. Wei, P. Chan and P. Weinstein. Corticotropin-releasing factor: a powerful inhibitor of vasogenic edema in cold-traumatized rat brain. Presented at the Tenth International Symposium on Microvascular Surgery for Cerebral Ischemia. San Francisco, July 13-15, 1990 (Abstract).

120. G.C. Gao, M.R. Dashwood and E.T. Wei. Corticotropin-releasing factor inhibition of substance P-induced vascular leakage in rats: possible sites of action. *Peptides* 12: 639-644, 1991.
121. E.T. Wei and G.C. Gao. Corticotropin-releasing factor: An inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. *Regulatory Peptides* 33: 93-104, 1991.
122. S.M. Serda and E.T. Wei. Corticotropin-releasing factor inhibits the acute inflammatory response of rat pawskin to cold injury, *Cryobiology* 28: 185-190, 1991.
123. S.M. Serda and E.T. Wei. Epinephrine-induced pulmonary edema in rats is inhibited by corticotropin-releasing factor. *Pharmacological Research* 26:85-91, 1992.
124. E.T. Wei, G.C. Gao and H.A. Thomas. Peripheral Anti-Inflammatory Actions of CRF. Ciba Foundation Symposium No. 172 on Corticotropin-Releasing Factor, D.J. Chadwick, J. Marsh and K. Ackrill (eds.), pg.258-268, 1993.
127. H.A. Thomas, N. Ling and E.T. Wei. CRF and Related Peptides as Anti-Inflammatory Agonist. In *3rd Hans Selye Symposium on Neuroendocrinology and Stress*, ed. Tache, Y., Rivier, C. Montreal, Canada, Oct. 11-14, 1992. *Annals of the New York Academy of Sciences* 697: 219-228, 1993.
125. E.T. Wei and H.A. Thomas. Anti-Inflammatory Peptide Agonists. *Annual Review of Pharmacology and Toxicology* 33:91-108, 1993.
126. G.C. Gao and E.T. Wei. Xenopsin, neurotensin, and neurotensin(8-13) and N-acetyl-neurotensin(8-13) inhibit vascular leakage in rats after tissue injury. *Journal of Pharmacology and Experimental Therapeutics* 265: 619-625, 1993.
128. H.A. Thomas, N. Ling, E.T. Wei, F. Berree, A. Cobas and H. Rapoport. Novel anti-inflammatory undecapeptides that contain anisoylated glutamic acid derivatives. *Journal of Pharmacology and Experimental Therapeutics* 267: 1321-1326, 1993.
131. E.T. Wei and H.A. Thomas. Correlation of neuroendocrine and anti-edema activities of alanine-corticotropin-releasing factor analogs. *European Journal of Pharmacology* 263: 319-321, 1994.
132. H.A. Thomas and E.T. Wei. Potent inhibition of thermal edema in rats by des-Tyr Dynorphin A. *Peptides* 6: 547-550, 1995.
133. G.C. Gao and E. T. Wei. Potencies of various neurotensin-(8-13) analogs for inhibition of heat-induced edema in the anesthetized rat. *Regulatory Peptides* 56: 41-48, 1995.
134. A.A. Kolobov, L.V. Olennikova, J.N. Tolparov, O.A. Kaurov, S.A. Ketlinsky, N.C. Ling, H.A. Thomas and E.T. Wei., Prototype mystixin peptides for pharmacological investigations. in *Peptides: Chemistry, Structure and Biology*, P.T.P. Kaumaya and R.S. Hodges (Eds.), Mayflower Scientific Ltd., 1995, pg. 199-200.

135. G.C. Gao and E.T. Wei, Inhibition of substance P-induced vascular leakage in rat by N-acetyl-neurotensin-(8-13), *Regul. Pept.* 58:117-121 (1995).
136. H.A. Thomas, L.T. Hunt, N. Fine and E.T. Wei. Similarities in amino acid sequences within corticotropin-releasing factor superfamily peptides, naringenin-chalcone synthase and annexin I. Abstracts of the Amer. Soc. Exptl. Biology Meeting, Atlanta, 1995.
137. G.P. Vlasov, S.V. Burov and V.K. Korolkov, H.A. Thomas and E.T. Wei. Analogs of Dynorphin A (6-12) with Anti-Inflammatory Activities. European Peptide Symposium, Edinburgh University, Scotland, 1996.
138. E.T. Wei, H.A. Thomas, J.S. Price, and T. Kishimoto, [D-Pro⁵]Corticotropin-releasing factor analogs as selective agonists at corticotropin-releasing factor receptors, *Eur. J. Pharmacol.* 306:161-164 (1996).
139. M.S. Harbuz, H.S. Chowdrey, S.L. Lightman, E.T. Wei and D.S. Jessop. An investigation into the effect of chronic infusion of corticotrophin-releasing factor on hind paw inflammation in adjuvant-induced arthritis. *Stress* 1:105-111,1996.
140. S. Ushiro, K. Mizoguchi, S. Yoshida, S. Jimi, T. Fujiwara, M. Yoshida, E.T. Wei, P. Kitabgi, S. Amagaya, M. Ono, and M. Kuwano, Stimulation of cell-surface urokinase-type plasminogen activator activity and cell migration in vascular endothelial cells by a novel hexapeptide analogue of neurotensin, *FEBS Lett.* 418:341-345 (1997).
141. N. Fazal, A. Slominski, M.A. Choudhry, E.T. Wei, and M.M. Sayeed, Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells, *FEBS Lett.* 435:187-190 (1998).
142. S. Iavicoli, E. Lopez-Perez, G.C. Buehring, H.A. Thomas, E.T. Wei, and T. Kishimoto, Bipolar-shape response of human neutrophils to corticotropin-releasing factor, *Eur. J. Pharmacol.* 349:301-306 (1998).
143. J.M. Quillan, W. Sadee, E.T. Wei, C. Jimenez, L. Ji, and J.K. Chang, A synthetic human Agouti-related protein-(83-132)-NH₂ fragment is a potent inhibitor of melanocortin receptor function, *FEBS Lett.* 428:59-62 (1998).
144. E.T. Wei, H.A. Thomas, E.A. Gjerd, R.K. Reed, S.V. Burov, V.I. Korolkov, O.V. Glynskaya, M.Y. Dorosh, and G.P. Vlasov, Dynorphin A(6-12) analogs suppress thermal edema, *Peptides* 19:767-775 (1998).
145. P. Baluk, N.W. Fine, H.A. Thomas, E.T. Wei, and D.M. McDonald, Anti-inflammatory mystixin peptides inhibit plasma leakage without blocking endothelial gap formation, *J. Pharmacol. Exp. Ther.* 284:693-699 (1998).
146. E.T. Wei, H.A. Thomas, H.C. Christian, J.C. Buckingham and T. Kishimoto. D-amino acid-substituted analogs of corticotropin-releasing hormone (CRH) and urocortin with selective agonist activity at CRH1 and CRH2 beta receptors. *Peptides* 19:1183-1190 (1998).

147. E.A.B. Gjerde, K.Woie, E.T. Wei and R.K. Reed. Corticotropin-releasing hormone inhibits lowering of interstitial pressure in rat trachea after neurogenic inflammation. *Eur. J. Pharmacol.* 352:99-102 (1998).
148. A.T. Slominski et al. Cutaneous expression of CRH and CRH-R: Is there a "Skin Stress Response System?" *Ann. N.Y. Acad. Sci.* 885: 287-311, 1999.
149. Gjerde,E.A., Woie,K., Wei,E.T., and Reed,R.K., Lowering of interstitial fluid pressure after neurogenic inflammation is inhibited by mystixin-7 peptide, *Am. J. Physiol Heart Circ. Physiol*, 279 (2000) H1377-H1382.
150. Slominski,A.T., Roloff,B., Zbytek,B., Wei,E.T., Fechner,K., Curry,J., and Wortsman,J., Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes, In *Vitro Cell Dev. Biol. Anim*, 36 (2000) 211-216.